MB-CART20.1 Lymphoma
This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent
BIOLOGICAL: MB-CART20.1
Phase I - Determination of the maximum tolerated dose (MTD), MTD is defined as the highest dose level at which \< 33% of patients experience Dose Limiting Toxicity (DLT). Safety and toxicity assessment of MB-CART20.1 per adverse events (AE) reporting classified according to CTCAE version 5.0., until day 28 after infusion of MB-CART20.1|Phase II - Best overall response rate, Response (Complete response (CR), Partial response (PR), Stable disease (SD), Progressive disease (PD)) is defined according to Cheson criteria., 3 months after infusion of MB-CART20.1
Phase I - Related safety and toxicity of MB-CART20.1, Per adverse events (AE) reporting classified according to CTCAE version 5.0., months 3, 6, 9 and 12 after infusion of MB-CART20.1|Phase I - Best overall response rate over 4 weeks and 3 months, Response (CR, PR, SD and PD) is defined according to Cheson criteria., 4 weeks and 3 months after infusion of MB-CART20.1|Phase I - Best overall response rate over 1 year, Response (CR, PR, SD and PD) is defined according to Cheson criteria., 1 year after infusion of MB-CART20.1|Phase I - Occurrence of B-cell aplasia, Circulating B cell numbers in the peripheral blood will be assessed by Flow cytometry., 1 year after infusion of MB-CART20.1|Phase I - Phenotype and Persistence of MB-CART20.1, Blood samples for determination of persistence/phenotyping of infused MB-CART20.1 will be analysed., 1 year after infusion of MB-CART20.1|Phase II - Best overall response rate over 1 year, Response (CR, PR, SD and PD) is defined according to Cheson criteria., 1 year after infusion of MB-CART20.1|Phase II - Overall response rate over 4 weeks and 3 months, Response (CR, PR, SD and PD) is defined according to Cheson criteria., 4 weeks and 3 months after infusion of MB-CART20.1|Phase II - Overall response rate over 1 year, Response (CR, PR, SD and PD) is defined according to Cheson criteria., 1 year after infusion of MB-CART20.1|Phase II - Number of patients with CR, PR, SD and PD, Response (CR, PR, SD and PD) is defined according to Cheson criteria., 1 year after infusion of MB-CART20.1|Phase II -Percentage of patients with CR, PR, SD and PD, Response (CR, PR, SD and PD) is defined according to Cheson criteria., 1 year after infusion of MB-CART20.1|Phase II - Safety and toxicity assessment of MB-CART20.1, Per adverse events (AE) reporting classified according to CTCAE version 5.0., 1 year after infusion of MB-CART20.1|Phase II - Occurrence of B-cell aplasia, Circulating B cell numbers in the peripheral blood will be assessed by Flow cytometry., 1 year after infusion of MB-CART20.1|Phase II - Phenotype and Persistence of MB-CART20.1, Blood samples for determination of persistence/phenotyping of infused MB-CART20.1 will be analysed., 1 year after infusion of MB-CART20.1
MB-CART20.1 consists of autologous Anti-CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in Non-Hodgkin-Lymphoma (NHL)